American Association of Endocrine Surgeons Publishes Guidelines for Thyroid Disease Surgery
The American Association of Endocrine Surgeons has published the first comprehensive guidelines for safe, effective, and appropriate thyroidectomy.
Graves’ Disease
Hyperthyroidism and Thyrotoxicosis: Diagnosis and Management
In most cases of overt hyperthyroidism, patients present with a constellation of symptoms, and appropriate treatment depends on the underlying mechanism.
Clinical Presentation of Graves Disease in Isolation vs With Other Autoimmune Disorders
Patients with Graves disease in association with other autoimmune diseases had a 4-fold higher rate of transition from initial hypothyroidism to hyperthyroidism compared with patients who had isolated Graves disease.
Teprotumumab BLA Submitted for Active Thyroid Eye Disease
Teprotumumab is an investigational fully human monoclonal antibody that works by inhibiting the insulin-like growth factor 1 receptor.
Teprotumumab Effectively Reduces Proptosis in Active Thyroid Eye Disease
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease.
Early Treatment for Hyperthyroidism Reduces CV Morbidity, Mortality in Graves Disease
Early and intensive treatment for hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, regardless of treatment method used.
Case Study: Young Woman With Abnormal Thyroid Function Tests
A patient with no thyroid-related symptoms presents with an abnormal thyroid function test.
Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
Maternal Graves disease and Hashimoto disease during pregnancy increases childhood risk for type 1 diabetes and schizophrenia, respectively.
Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
Active Ophthalmopathy Benefits From Teprotumumab Treatment
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
Next post in Thyroid
